Immunogenicity

HOOKIPA announces positive preliminary Phase 1 immunogenicity data for its immunotherapy candidates to treat advanced HPV16+ cancers

Saturday, April 10, 2021 - 1:31pm

The data were presented today at a late-breaker poster session at the virtual American Association for Cancer Research Annual Meeting.

Key Points: 
  • The data were presented today at a late-breaker poster session at the virtual American Association for Cancer Research Annual Meeting.
  • As we are still exploring optimal dosing, these early responses are particularly encouraging, said Joern Aldag, Chief Executive Officer of HOOKIPA.
  • Preliminary data showed a strong antigen-specific T cell response after one dose of HB-201 or HB-202, based on direct Enzyme-Linked ImmunoSpot (ELISpot) T cell analysis.
  • Other preliminary immunogenicity data highlight immune system activation following a single dose of HB-201.

Portage Biotech Highlights First Patient Dosed in PRECIOUS-01 Study of PORT-3 for the Treatment of NY-ESO-1 Positive Solid Tumors

Thursday, April 8, 2021 - 2:00pm

PORT-3 is a nanoparticle co-formulation of the invariant natural killer T-cell (iNKT) agonist IMM60 and NY-ESO-1 immunogenic peptides developed for the treatment of NY-ESO-1 positive solid tumors.

Key Points: 
  • PORT-3 is a nanoparticle co-formulation of the invariant natural killer T-cell (iNKT) agonist IMM60 and NY-ESO-1 immunogenic peptides developed for the treatment of NY-ESO-1 positive solid tumors.
  • "Preclinical studies of both compounds have shown that treatment can lead to a broad reprogramming of the immune system.
  • This has the potential to increase the specificity of treatment, including targeting specific tumor markers, and increasing the effectiveness of treatment.
  • For more information, please visit www.portagebiotech.com , follow us on Twitter at @PortageBiotech or find us on LinkedIn at Portage Biotech Inc.

EQS-News: ACM Biosciences closes first financing round to accelerate the development of its polymersome vaccine platform and a second-generation COVID-19 vaccine

Wednesday, April 7, 2021 - 7:00am

The proprietary Artificial Cell Membranes (ACMs) are based on an innovative nanotechnology platform using non-immunogenic polymersomes as its carrier.

Key Points: 
  • The proprietary Artificial Cell Membranes (ACMs) are based on an innovative nanotechnology platform using non-immunogenic polymersomes as its carrier.
  • With the necessary financial resources secured, ACM Biosciences will now accelerate its development of the COVID-19 vaccine candidate and proceed with the running mRNA vaccine proof of concept stability and immunogenicity studies.
  • Their preclinical efficacy data are really exciting, and their vaccine candidate should be taken into clinical trials as quickly as possible."
  • ACM Biosciences technology allows great variability because its polymersome platform is highly customizable and can be made compatible with different vaccine formats, including mRNA and protein antigens.

OSE Immunotherapeutics Receives Authorization for Phase 1 Clinical Trial of its Multi-Target Multi-Variant COVID-19 Vaccine

Thursday, April 1, 2021 - 5:00pm

CoVepiT is based on the identification of multiple immuno-dominant epitopes that generate a T memory lymphocyte response and combining them in the vaccine.

Key Points: 
  • CoVepiT is based on the identification of multiple immuno-dominant epitopes that generate a T memory lymphocyte response and combining them in the vaccine.
  • The objective of the clinical development for our next-generation vaccine CoVepiT is to evaluate its safety and benefit, particularly for people at risk, i.e., vulnerable populations.
  • This Phase 1 clinical trial will evaluate the safety, reactogenicity and immunogenicity of CoVepiT in healthy adult volunteers.
  • FR104 (anti-CD28 monoclonal antibody): positive Phase 1 results; ongoing Phase 1/2 in renal transplant, Phase 2-ready asset in a niche indication in autoimmune diseases.

Altimmune Reports Data from its Phase 1b Clinical Trial of NasoShield™

Thursday, April 1, 2021 - 12:00pm

GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate.

Key Points: 
  • GAITHERSBURG, Md., April 01, 2021 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, reported clinical data today on its NasoShield intranasal anthrax vaccine candidate.
  • The Phase 1b trial evaluated the safety and immunogenicity of one and two-dose regimens of NasoShield in healthy volunteers.
  • The trial enrolled 42 healthy subjects who received intranasally administered NasoShield or saline placebo and were then monitored for 6 months post-dosing.
  • The clinical data from the Phase 1b trial showed that:
    Serum binding antibody responses to the protective antigen of Bacillus anthracis, the bacterium and causative agent of anthrax, were significantly greater than in the placebo arm.

TOT BIOPHARM Announces A Number of Key Anti-Tumor Drugs Have Entered the Pivotal Clinical Stage in 2020

Tuesday, March 23, 2021 - 10:35pm

TOT BIOPHARM's core products including mAb drug TAB008 and ADC drug TAA013 have achieved key milestones.

Key Points: 
  • TOT BIOPHARM's core products including mAb drug TAB008 and ADC drug TAA013 have achieved key milestones.
  • The clinical results show that TAB008 has similar efficacy, safety, immunogenicity and pharmacokinetics profiles with the brand-name formulation of bevacizumab.
  • -- In 2020, the GMP compliance inspection of the production workshop for chemical drugs was completed, laying a foundation for the commercial production of chemical drugs.
  • commercial collaboration for drug candidates: At present, TOT BIOPHARM has multiple product pipelines such as biological drugs, ADC drugs and chemical drugs, which are stepping into the commercial stage with huge market potential.

Agilex Biolabs Showcases Advanced Immunoassay and Immunobiology Services at Bio-Europe Spring 2021

Wednesday, March 17, 2021 - 7:00am

ADELAIDE, AU, Mar 17, 2021 - (ACN Newswire) - Agilex Biolabs, Australia's largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced it will showcase its world-class immunoassay and immunobiology services for regulated bioanalysis at Bio-Europe 2021.

Key Points: 
  • ADELAIDE, AU, Mar 17, 2021 - (ACN Newswire) - Agilex Biolabs, Australia's largest and most technologically advanced specialist bioanalytical laboratory for clinical trials, today announced it will showcase its world-class immunoassay and immunobiology services for regulated bioanalysis at Bio-Europe 2021.
  • Sales Agilex Biolabs' Director Immunoassay said:
    "Our experienced team can develop or transfer a method for any biologic to support pre-clinical GLP or clinical studies.
  • Agilex Biolabs also features a rebate of up to 43.5% on clinical trial bioanalytical services spend as part of the Australian Government clinical trial attraction program.
  • We offer services for both small molecules and biologics for PK, immunogenicity (PD) and biomarker bioanalysis utilising the two platforms of LC-MS/MS and Immunoassay.

Repertoire Immune Medicines Pre-publishes New Research Identifying Potential Mechanisms for Immune Escape of SARS-CoV-2 Variants to Support Novel Approaches for T Cell Based Therapeutic Development

Wednesday, March 3, 2021 - 2:40pm

This research indicates how SARS-CoV-2 variants may avoid immune surveillance and informs the design of new T cell-based vaccines that can provide long term immunity.

Key Points: 
  • This research indicates how SARS-CoV-2 variants may avoid immune surveillance and informs the design of new T cell-based vaccines that can provide long term immunity.
  • The results also highlight the ability of Repertoires proprietary DECODE platform to identify T cells and the disease relevant epitopes that they engage, supporting the development of novel immune medicines.
  • Understanding T cell engagement at the precise epitope level should guide the development of novel therapeutic approaches beyond applications to SARS-CoV-2.
  • To learn more about Repertoire Immune Medicines, please visit our website: www.repertoire.com and follow us on LinkedIn and Twitter .

Selecta Biosciences Announces Science Advances Publication Highlighting Potential Potency and Durability Benefits of ImmTOR™ in Gene Therapy

Wednesday, February 24, 2021 - 9:15pm

These findings underscore the promise of Selectas ImmTOR platform to address current limitations, notably immunogenicity, safety and durability, of gene therapy.

Key Points: 
  • These findings underscore the promise of Selectas ImmTOR platform to address current limitations, notably immunogenicity, safety and durability, of gene therapy.
  • The results in this publication continue to expand our knowledge of and validate the benefits of co-administering ImmTOR with AAV gene therapies, said Carsten Brunn, Ph.D., president and chief executive officer of Selecta.
  • We look forward to continuing to investigate the benefits of adding ImmTOR to gene therapy in clinical studies this year.
  • Selecta Biosciences Inc. (NASDAQ: SELB) is leveraging its clinically validated ImmTOR platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses.

AC Immune to Highlight Promising Alzheimer’s Vaccine at the SVB Leerink 10th Annual Global Healthcare Conference

Wednesday, February 17, 2021 - 12:00pm

LAUSANNE, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10th Annual Global Healthcare Conference, taking place virtually on February 2226, 2021.

Key Points: 
  • LAUSANNE, Switzerland, Feb. 17, 2021 (GLOBE NEWSWIRE) -- AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical-stage biopharmaceutical company with a broad pipeline focused on neurodegenerative diseases, today announced that it will participate in the upcoming SVB Leerink 10th Annual Global Healthcare Conference, taking place virtually on February 2226, 2021.
  • During a fireside chat, AC Immune CEO Prof. Andrea Pfeifer will discuss the Companys execution strategy to advance and accelerate its precision medicine approach to targeting neurodegenerative diseases.
  • Prof. Pfeifer will also highlight AC Immunes novel anti-phospho-Tau (pTau) vaccine candidate ACI-35.030, including recent interim Phase 1b/2a results that showed promising immunogenicity and safety in patients with early Alzheimers disease.
  • AC Immune SA is a Nasdaq-listed clinical-stage biopharmaceutical company, which aims to become a global leader in precision medicine for neurodegenerative diseases.